Home > Journals > Giornale Italiano di Dermatologia e Venereologia > Past Issues > Giornale Italiano di Dermatologia e Venereologia 2020 June;155(3) > Giornale Italiano di Dermatologia e Venereologia 2020 June;155(3):325-31

CURRENT ISSUE
 

JOURNAL TOOLS

eTOC
To subscribe
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Publication history
Reprints
Permissions
Cite this article as

 

ORIGINAL ARTICLE   Freefree

Giornale Italiano di Dermatologia e Venereologia 2020 June;155(3):325-31

DOI: 10.23736/S0392-0488.18.05974-6

Copyright © 2018 EDIZIONI MINERVA MEDICA

language: English

Analysis of neoplastic skin complications in transplant patients: experience of an Italian multidisciplinary transplant unit

Barbara MARCONI, Anna CAMPANATI, Melania GIANNONI , Francesca RICOTTI, Tommaso BIANCHELLI, Annamaria OFFIDANI

Dermatological Clinic, Department of Clinical and Molecular Sciences, Università Politecnica delle Marche (UNIVPM), Ancona, Italy



BACKGROUND: Transplant patients need to be strictly followed, since the immunosuppressive therapies they usually receive can increase the risk of skin complications. This study aims to evaluate the prevalence of neoplastic skin complications in transplant patients.
METHODS: We analyzed 256 liver or kidney transplant patients. The follow-up mean period was 7±3.5 years. It was also evaluated the prevalence of cutaneous neoplastic complications according to the immunosuppressive regimen received by patients as follows: cyclosporine, tacrolimus, steroids, mycophenolate mofetil or everolimus, in single, double or triple therapy.
RESULTS: The 18.36% of patients developed neoplastic complications, among these 9.37% actinic keratoses, 8.20% non-melanoma skin cancer, and 0.78% cutaneous melanoma. Among patients who developed non melanoma skin cancer, 61.90% had basal cell carcinoma, 23.81% squamous cell carcinoma, 52% Kaposi’s sarcoma and 4.76%, Malherbe’s epithelioma.
CONCLUSIONS: This study demonstrated the increased risk of skin cancer in transplant patients during the first 7 years of follow-up and made the dermatologists aware about the need of a regular cutaneous follow-up for this subset of patients.


KEY WORDS: Transplants; Immunosuppression; Skin neoplasms

top of page